Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Boxer Capital, LLC has filed a new 13G, reporting 5.3% ownership in $ESPR - https://fintel.io/so/us/espr
I posed the following rhetorical question last Sunday, the 19th, before becoming aware of the results reached by ESPR on Monday, the 20th. I have not reached any contrary answer to the question as yet.
"Should I be interested in any of the companies that have reacted negatively to the results posted by AMGN for Repatha, apart from other entities/items present in respective pipelines"?
Currently I am not interested. My own monthly cost for AMRN's Vascepa is much lower---$37/month co-pay for my off-label prescription---than the prognosticated cost of Repatha[$14,500/year] or ESPR's treatment drug[estimated $3000/year]. The benefits of Vascepa for me seem to = or exceed anything Repatha or competition, including ESPR, would offer in CVD arena. My 2016 lipid panel data is posted on the Amarin IHub board. The data is from blood samples taken at my last annual physical in March 2016, and will be up-dated in March 2017. I will be 80 years old in April 2017.
The EPA/AA ratio is becoming widely recognized as a marker for inflammation in the CV system---my value of 1.3 is particularly good, probably better than the vast majority of the U.S. population. My doctor termed my lipid profile as "excellent," and my cardiovascular risk as "optimally suppressed."
Below are the current lipid panel marker values for me. I have been prescribed Vascepa[an oral capsule containing 96%(1 gram) of an omega-3 fatty acid known as EPA, or icosapent ethyl], Off-label, since 4/1/2013.
Generic Zocor = 40 mg dose > 20 years. T1 diabetic since 1957.
HbA1c = 6.5; FBG= 111 mg/dL
Total cholesterol = 144 mg/dL
LDL-C = 70 mg/dL
TGCs = 63. "
HDL = 61. "
VLDL = 13. "
C-reactive
protein = 2.2 mg/L
APO B = 60 mg/dL;
Lp-PLA2 = 216, termed very slightly elevated;
EPA/AA Ratio = 1.3;
Omega-6/Omega-3 ratio = 1.8;
EPA = 7.0% ;
AA = 5.3%;
DHA = 2.1%;
Omega-3(EPA + DHA) Index = 9.1%, optimal > 3.2%
Vascepa also obliterated the DES I once had within days of 1st dose in April 2013. DES remains gone today. Vascepa has no known side effects. AGN and SHPG should be concerned also to the extent reliance is had for their respective DES treatments to be accretive to revenue and earnings.
Is DES one of the secondary or tertiary indications/utilities for which Amarin may file with the FDA per its 1st Amendment settlement with FDA last year? Further background of Amarin and Vascepa may be found here:
http://www.fdalawblog.net/Amarin%20%2800193135%29.pdf
http://tinyurl.com/zyduacf
http://tinyurl.com/jabzuvw
http://tinyurl.com/jumnoej
http://tinyurl.com/zoxx9x4
http://tinyurl.com/zb8rnqu
http://tinyurl.com/jnx6w6p
Read results, conclusions and discussion sections from the following:
http://www.internationaljournalofcardiology.com/article/S0167-5273(16)33563-X/fulltext
I will post more on your costs analysis later. Suffice to say I copay $111 every 3 months for my prescription, off-label, for an already FDA-approved drug from Amarin[AMRN] called Vascepa[an omega-3 fatty acid containing oral capsule, 96% EPA = 1 gram, taken 2 capsules in morning with breakfast, 2 with dinner].
Time to load the $41s stopped making new lows on the 15-minute
Solid follow through from yesterday, wouldn't be surprised to see it double from these levels, news was excellent yesterday. Play is so undervalued.
$ESPR:PM up 2.3%
Market now a believer of bempedoic acid which
-Lowers LDL
-Lowers hsCRP
-Works in statin in-intolerant patients
-Orally effective
-CHEAP (Bempedoic Acid only $3,000 to treat vs $14,500 Statins)
Someone (Very Knowledgeable on Biotech) I follow on another Message board said something to the effect:
With $AMGN's repatha being priced out of mkt, bemp may b the only game in town4 0.20x 70million pts.
If you take 20% of 70Mil Patients x $3,000 = $42Billion Drug!!
Now, $ESPR Bempedoic Acid Drug = $42Billion / 23Mil shares = $1,826 Share price. Can you see why $AMGN , $MRK would want to Purchase Esperion? Hence TODAY's VOLUME.
Me thinks we go HIGHER tomorrow
ESPR: Bempedoic Acid CVOT 75% chance of success. Proven Mechanism, Clear Path to Approval; Team of Lipid Experts... Well Funded.
In June of 2015, Analyst's had PTs from JMP $177, UBS $140 & Barclays $150. When ESPR was trading $100+.
Bempedoic acid was safe & effective in statin-intolerant patients -20% of all w/ lipid disorder. That's the advantage
Esperion Benefit from Trump Administration?
https://www.forbes.com/forbes/welcome/?toURL=https://www.forbes.com/sites/matthewherper/2017/03/20/is-esperion-therapeutics-going-to-benefit-from-a-trump-fda/&refURL=https://t.co/DawlFX1ubm&referrer=https://t.co/DawlFX1ubm
Glad I backed up the truck on Friday.
Stock traded 100+ previously prior to FDA requiring CVOT. Now with Clear path to Approval, could get past $100 again. Investors also have to wonder if someone like AMGN, MRK, or ? would jump in and buy Esperion and their renown team of Lipid Experts.
Big Short Position also caught in today's squeeze. Traded 106,000 shares after hours and I think ended around $41.60 up 30cents.
$ESPR' bempedoic acid:
Orally active
lowers LDL & hsCRP - helps reduce inflammation
clean safety profile
will b a lot CHEAPER than PCSK9i drugs
Do your own DD & GL!
Nice move! An offering is inevitable... make money on the move up and down.
Good stuff! Traded 3 times all green. Man what a Monday......
What IP protection does ESPR have for the FDA-approved molecule and its use?....I am not a trader, and I have not followed ESPR at all. I would be concerned that its technology might be embraced by some other entity's patents, from a long-term perspective.
Buy a put toward the close today?
I'll be honest, i'm not sure, I haven't read the delay but it's a traders delight so far today wow. ATM$$$$$$$$$$ Another short cover before close? there was a lot of short action $34-$36 when it pulled back.
http://ih.advfn.com/p.php?pid=nmona&article=74132312
Does it seem today's gain is out-sized in light of delayed plans to file NDA in 2019?
Sold $35 let it correct, ride the next wave.
Damn, the 3k shares bought a couple hours before close are looking nice now.
It's over $30 in pre-market.
Will be back above $26 this week.
http://www.bioworld.com/content/fourier-clinical-benefit-yes-cost-benefit-no-0
Repatha's cost would be about $14,500 a year. ESPR ETC-1002 is only $3,000 a year. And Orally vs. Shot. And less Inflammation.
ESPR was the hardest-hit company yesterday in the fallout from AMGN's Repatha-CVOT presentation:
#msg-129644330
How do you explain that?
$ESPR bempedoic acid ETC-1002:
-much lower cost,
-lowers hsCRP/inflammation
-better safety profile
-orally effective
-suited4 statin-intolerant Pts
ESPR monster. Love the swing trading on this one
Despite today's 29% pop, the Repatha CVOT is not necessarily a big win for LDL-lowering drugs—see #msg-128416849.
13.89 nice close. ESPR low float monster
They missed their end of September line.
It will probably be another week or so before we hear anything.
Buy? mmm what?
Looking for $8's to make 1st entry at which time the already strong callbids should get even stronger - then would look to write some calls?
Do you have a $$$ entry point here?
Dew Have U looked at PRTO ?
My wife works with dialysis patients , she did CKD research at Yale.
Her Renal Dept has been recruiting for PRTO's PATENCY 1 and PATENCY 2 trials .
These trials are double blinded, folks ...no insider info here .
Anyway Dew I'll give you what I have and would appreciate your comments .
Novartis originally had an option on their program ( to improve / maintain patency ( blood flow ) in fistulas , essential for dialysis )
They declined to exercise their option $550m ...or at least they couldn't come to terms .
PRTO IPO'd at $10 a share in 2014 and went ahead on their own ...almost sound like the ZSPH story ( hyperkalemia )
Phase 3 PATENCY 1 was enrolled ahead of schedule and should read out in Dec 2016
Phase 3 PATENCY 2 seemed to have a slowed / delayed enrollment ...may be related to slight change/emphasis in end points ...see clinicaltrials.gov history of changes but is up and running now.
PRTO has funds thru 2017 ...enough to finish PATENCY 1 , but not enough to finish PATENCY 2 . Believe their program is Fast Tracked and also Orphan Drug designated..
PRTO presented at a recent conference ...Webcast is available thru their web site
They also filed a CT order ... SEC confidential treatment order..so I'm wondering if they are back in talks with Novartis ...who you may know has a presence in Renal.
Believe its now Abingworth LLP's 2nd largest position .
Baker Bros and Alta Partners also have positions .
So about Fistula's ( AVF ) and dialysis .
Fistula blockage is a major problem for dialysis patients . My wife deals with it every week. Some of her patients have fistula tracks completely up both arms ...as one fails they start a new one higher up.
Hospitals spend around $17,000 per dialysis patient maintaining or reworking fistula's...PRTO's figures.
So there is a real demand for anything that will reduce Fistula failure.
PRTO thinks they can reduce Fistual failure by 20-30 % with their Vonapantise drug ( applied during creation of the Fistula )
Would appreciate your comments
PRTO has spiked recently ( post conference and CT order )
Thx
Kiwi
PS for anyone else reading this . If their P 3 trial fails , this stock is going to a $1. Risk only what you can afford to lose.
Typo: Meant to say surrogate marker (not market).
$9.66 close. Should bounce.
LDL not an ironclad surrogate market, FDA says: #msg-123585201.
RBC drastically cuts price target: #msg-119158985.
Hello Stocktrademan. You looking to buy or sell short?
$ESPR recent news/filings
bearish 26.75
## source: finance.yahoo.com
Fri, 13 Nov 2015 18:04:21 GMT ~ ESPERION THERAPEUTICS, INC. Financials
read full: http://finance.yahoo.com/q/is?s=espr
*********************************************************
Thu, 12 Nov 2015 23:49:17 GMT ~ Lightning Round: It's nowhere near bottoming yet
read full: http://www.cnbc.com/id/103164511?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=103164511
*********************************************************
Thu, 12 Nov 2015 23:25:00 GMT ~ Cramer: I'm staying away from solar
read full: http://finance.yahoo.com/video/cramer-im-staying-away-solar-232500149.html
*********************************************************
Fri, 06 Nov 2015 14:04:19 GMT ~ Esperion Therapeutics to Present at November Healthcare Conferences
[at noodls] - November 6, 2015 ANN ARBOR, MI -- (Marketwired) -- 11/06/15 -- Esperion Therapeutics, Inc.(NASDAQ: ESPR), a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density ...
read full: http://www.noodls.com/view/469E1EE69725B2494C35AFD0D6048130A1504775
*********************************************************
Fri, 06 Nov 2015 13:30:00 GMT ~ Esperion Therapeutics to Present at November Healthcare Conferences
[Marketwired] - Esperion Therapeutics, Inc. , a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol lowering therapies for the treatment of patients ...
read full: http://finance.yahoo.com/news/esperion-therapeutics-present-november-healthcare-133000217.html
*********************************************************
$ESPR charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$ESPR company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/ESPR/company-info
Ticker: $ESPR
OTC Market Place: Not Available
CIK code: not found
Company name: Esperion Therapeutics, Inc.
Incorporated In:
Business Description:
$ESPR share structure
## source: otcmarkets.com
Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available
$ESPR extra dd links
Company name: Esperion Therapeutics, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/ESPR/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/ESPR/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=ESPR+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=ESPR+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=ESPR+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/ESPR/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/ESPR/news - http://finance.yahoo.com/q/h?s=ESPR+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/ESPR/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/ESPR/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/ESPR/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/ESPR/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/ESPR/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/ESPR/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/ESPR/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/ESPR/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=ESPR+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/ESPR
DTCC (dtcc.com): http://search2.dtcc.com/?q=Esperion+Therapeutics%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Esperion+Therapeutics%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Esperion+Therapeutics%2C+Inc.&x=0&y=0
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/ESPR/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/ESPR
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/ESPR/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/ESPR/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/ESPR/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/ESPR/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/ESPR/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/ESPR/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/ESPR/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=ESPR&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=ESPR
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/ESPR/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=ESPR+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=ESPR+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=ESPR
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=ESPR
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=ESPR+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/ESPR/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=ESPR+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/ESPR.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=ESPR
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/ESPR/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/ESPR/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/ESPR/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/ESPR/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/ESPR
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/ESPR
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/ESPR:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=ESPR
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=ESPR
$ESPR DD Notes ~ http://www.ddnotesmaker.com/ESPR
Still that $4 plus ESPR bounce was a beauty today.
Followers
|
37
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
343
|
Created
|
12/09/13
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |